NCT06064656

A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Clinical Characteristics and Mortality in Patients With Fibrodysplasia Ossificans Progressiva (FOP): A Non-Interventional US National Retrospective Cohort

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 131 (actual)
• Sponsor: Regeneron Pharmaceuticals · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Primary Objective(s): * To describe the demographic characteristics of people living with FOP and a matched cohort of non-FOP people living in the United States (U.S.) * To describe the prevalence of clinical characteristics of interest and the use of key medications in people living with FOP and a matched cohort of non-FOP people living in the U.S. * To compare the prevalence of key clinical characteristics and medication use in people living with FOP to a matched cohort of non-FOP people living in the U.S. * To estimate the crude mortality rate among people living with FOP

Conditions

• Fibrodysplasia Ossificans Progressiva (FOP)

Interventions

Type	Name	Description
OTHER	Non-Interventional	No study treatment will be administered in this study.

Timeline

• Start date: 2023-06-29
• Primary completion: 2023-09-22
• Completion: 2023-09-29
• First posted: 2023-10-03
• Last updated: 2025-07-03

Locations

1 site across 1 country: United States